Biotech Values

[ghmm]

EU Rheumatoid Arthritis Landscape Poised for Big Changes as Rheumatologists Plan for the Adoption of Eli Lilly/Incyte's Olumiant, Pfizer's Xeljanz, and Regeneron/Sanofi's Kevzara

Don't know credibility of the company doing the research (seems logical given likely much lower cost among other benefits) if accurate bodes well for JAK inhibitors.

http://www.prnewswire.com/news-releases/eu-rheumatoid-arthritis-landscape-poised-for-big-changes-as-rheumatologists-plan-for-the-adoption-of-eli-lillyincytes-olumiant-pfizers-xeljanz-and-regeneronsanofis-kevzara-300451672.html

if asked to choose between a new JAK inhibitor and a new IL-6 inhibitor, 74% would prefer the JAK.